WeTrials
Recruiting

An Open-label, Phase 1, Multicentre Platform Study to Evaluate the Safety and Preliminary Anti-tumour Activity of NT-175 in Human Leukocyte Antigen-A*02:01-Positive Adult Participants With Advanced Malignancies That Are Positive for the TP53 R175H Mutation

What is this study?

This early-stage study is testing a new experimental treatment called NT-175 for adults with advanced cancers. The treatment uses modified immune cells to specifically target a genetic change known as the TP53 R175H mutation.

Who can participate?

Adults aged 18 and older who have specific types of advanced cancer, such as colorectal, pancreatic, or breast cancer, may be able to join. Participants must also meet certain genetic and health requirements to ensure safety.

What will happen?

Participants will receive the experimental cell therapy and be closely monitored by the medical team for safety and to see how well the treatment fights the cancer.

Where and when?

This study is currently recruiting patients at medical centers in locations including Arizona and California in the United States.

Key Points
  • 1Testing a new engineered cell therapy for advanced cancers.
  • 2Specifically looks for the TP53 R175H genetic mutation.
  • 3Currently recruiting participants at select U.S. locations.

Related links

Outside pages about this study, checked by our team

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Non-small Cell Lung CancerHead and Neck Squamous Cell CarcinomaColorectal CarcinomaPancreatic AdenocarcinomaBreast CancerOther Solid TumorsOvarian CancerMyeloid Neoplasms (AML/MDS)

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.